Haven Manufacturing Acquired by CORE Industrial Partners Portfolio Company CGI Automated Manufacturing

Haven Manufacturing acquired: CORE Industrial Partners (“CORE”), a Chicago-based private equity firm, announced today the acquisition of Haven Manufacturing (“Haven” or the “Company”), a full-service contract manufacturer of highly engineered components, by CORE portfolio company CGI Automated Manufacturing (“CGI”).

Haven Manufacturing is the fourth add-on acquisition to the CGI platform launched by CORE in August 2021.

Specializing in components for medical devices, medical equipment, and related applications, Haven provides a full suite of manufacturing services, including design assistance, prototyping, EDM, waterjet, laser etching, blasting, grinding, and passivation, as well as broad CNC machining capabilities to supply precision parts in lengths from less than one inch up to 85 inches. The Company’s metrology division augments its medical products manufacturing focus, providing contract measurement services for the medical, aerospace & defense, industrial, and consumer end markets.

Founded in 1966, Haven operates two facilities with more than 60,000 total square feet in Grand Haven, Michigan, and Ossian, Indiana. The Company holds ISO 13485, ISO 9001, and ISO 17025 certifications and is both FDA-registered and ITAR-compliant.

TJ Chung, the Senior Partner of CORE and Chairman of CGI, said, “Haven is strategically located to serve leading medical device and equipment manufacturers in Northeast Indiana and Southwest Michigan. The Company’s deep experience in the medical end market fits extremely well with CGI’s focus on serving attractive, growing industries requiring tight tolerances for mission-critical applications.”

Len Feddema, President of Haven Manufacturing, said, “My partners and I believe in the fundamental element of teamwork, with pride and respect for our employees and customers. We believe the quality of the entire team and its involvement in problem-solving has been and continues to be, the crucial component to our success. In collaboration with CGI and CORE, we’re excited to expand beyond Haven to even better serve our valued customers.”

Winston & Strawn LLP provided legal representation to CGI and CORE in the transaction.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version